AMRUBICIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H25NO9
Molecular Weight	483.4673
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C3=C(C1)C(O)=C4C(=O)C5=CC=CC=C5C(=O)C4=C3O

InChI

InChIKey=VJZITPJGSQKZMX-XDPRQOKASA-N

InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C25H25NO9
Molecular Weight	483.4673
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26750506 | https://mink.nipponkayaku.co.jp/product/di/in_file/sedi_cali_in.pdf

Amrubicin is a totally synthetic 9-aminoanthracycline anticancer drug, which is approved in Japan for the treatment of small cell and non-small cell lung cancer. Upon administration amrubicin is reduced to its C-13 hydroxy metabolite, amrubicinol. The cytotoxicity of amrubicinol in vitro is 10 to 100 times greater than that of amrubicin. Thus, the anticancer activity of amrubicin is considered to derive from this active metabolite. The mechanism of action of the drug is related to the inhibition of topoisomerase II by stabilizing the cleavable complex.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA topoisomerase II 66 Target ID: CHEMBL2094255 Sources: https://mink.nipponkayaku.co.jp/product/di/in_file/sedi_cali_in.pdf	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Small-cell lung cancer 41 Sources: https://mink.nipponkayaku.co.jp/product/di/in_file/sedi_cali_in.pdf	Primary		Approved 8583	CALSED Approved Use Non small cell lung cancer, small cell lung cancer. Launch Date 2002
Non-small cell lung cancer 211 Sources: https://mink.nipponkayaku.co.jp/product/di/in_file/sedi_cali_in.pdf	Primary		Approved 8583	CALSED Approved Use Non small cell lung cancer, small cell lung cancer Launch Date 2002

C_max

Value	Dose	Analyte	Population
3407 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	45 mg/m² 1 times / day multiple, intravenous dose: 45 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4869 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	40 mg/m² 1 times / day multiple, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3349 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	35 mg/m² 1 times / day multiple, intravenous dose: 35 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1867 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	30 mg/m² multiple, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
94 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	45 mg/m² 1 times / day multiple, intravenous dose: 45 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
333 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	40 mg/m² 1 times / day multiple, oral dose: 40 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
162 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	35 mg/m² 1 times / day multiple, intravenous dose: 35 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
87 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	30 mg/m² multiple, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1693 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	30 mg/m² 1 times / day multiple, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3414 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	35 mg/m² 1 times / day multiple, intravenous dose: 35 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4869 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	40 mg/m² 1 times / day multiple, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
77 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	30 mg/m² 1 times / day multiple, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
170 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	35 mg/m² 1 times / day multiple, intravenous dose: 35 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
333 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	40 mg/m² 1 times / day multiple, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3329 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23400695/	40 mg/m² single, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4024 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23400695/	40 mg/m² 1 times / day multiple, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
26.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23400695/	40 mg/m² single, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
42.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23400695/	40 mg/m² 1 times / day multiple, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7290 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22237957/	65 mg/m² 1 times / week multiple, intravenous dose: 65 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7919 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22237957/	60 mg/m² 1 times / week multiple, intravenous dose: 60 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
64.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22237957/	65 mg/m² 1 times / week multiple, intravenous dose: 65 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
44.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22237957/	60 mg/m² 1 times / week multiple, intravenous dose: 60 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
13490 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	45 mg/m² 1 times / day multiple, intravenous dose: 45 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
16706 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	40 mg/m² 1 times / day multiple, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13447 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	35 mg/m² 1 times / day multiple, intravenous dose: 35 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10262 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	30 mg/m² multiple, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2585 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	45 mg/m² 1 times / day multiple, intravenous dose: 45 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4097 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	40 mg/m² 1 times / day multiple, oral dose: 40 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2325 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	35 mg/m² 1 times / day multiple, intravenous dose: 35 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1514 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16418698/	30 mg/m² multiple, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8601 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	30 mg/m² 1 times / day multiple, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13071 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	35 mg/m² 1 times / day multiple, intravenous dose: 35 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
16706 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	40 mg/m² 1 times / day multiple, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1361 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	30 mg/m² 1 times / day multiple, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2476 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	35 mg/m² 1 times / day multiple, intravenous dose: 35 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4097 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	40 mg/m² 1 times / day multiple, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1968 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23400695/	40 mg/m² single, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2152 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23400695/	40 mg/m² 1 times / day multiple, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
378 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23400695/	40 mg/m² single, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
624 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23400695/	40 mg/m² 1 times / day multiple, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5279 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22237957/	65 mg/m² 1 times / week multiple, intravenous dose: 65 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5737 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22237957/	60 mg/m² 1 times / week multiple, intravenous dose: 60 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
265 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22237957/	65 mg/m² 1 times / week multiple, intravenous dose: 65 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
378 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22237957/	60 mg/m² 1 times / week multiple, intravenous dose: 60 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
4.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	30 mg/m² 1 times / day multiple, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	35 mg/m² 1 times / day multiple, intravenous dose: 35 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	40 mg/m² 1 times / day multiple, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	30 mg/m² 1 times / day multiple, intravenous dose: 30 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
18 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	35 mg/m² 1 times / day multiple, intravenous dose: 35 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
17.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16028099/	40 mg/m² 1 times / day multiple, intravenous dose: 40 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22237957/	65 mg/m² 1 times / week multiple, intravenous dose: 65 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.63 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22237957/	60 mg/m² 1 times / week multiple, intravenous dose: 60 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICIN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22237957/	65 mg/m² 1 times / week multiple, intravenous dose: 65 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22237957/	60 mg/m² 1 times / week multiple, intravenous dose: 60 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMRUBICINOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
40 mg/m2 1 times / day multiple, intravenous MTD Dose: 40 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 40 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16028099/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16028099/	Other AEs: Febrile neutropenia, Arrhythmia... Other AEs: Febrile neutropenia (grade 3, 1 pt) Arrhythmia (grade 3, 1 pt) Neutropenia (grade 4, 1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/16028099/
50 mg/m2 1 times / day multiple, intravenous MTD Dose: 50 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16012792/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16012792/	Other AEs: leukopenia, Neutropenia... Other AEs: leukopenia (3 patients) Neutropenia (3 patients) thrombocytopenia (3 patients) Melaena (3 patients) Hematemesis (3 patients) nausea (3 patients) vomiting (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/16012792/
65 mg/m2 1 times / week multiple, intravenous MTD Dose: 65 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 65 mg/m2, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/22237957/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/22237957/	Other AEs: Aspartate aminotransferase increase, Alanine aminotransferase increase... Other AEs: Aspartate aminotransferase increase (grade 3, 1 pt) Alanine aminotransferase increase (grade 3, 1 pt) Febrile neutropenia (grade 3, 1 pt) Neutropenia (grade 4, 1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/22237957/
30 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 30 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 30 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16028099/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16028099/	Other AEs: Thrombocytopenia... Other AEs: Thrombocytopenia (grade 3, 1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/16028099/
35 mg/m2 1 times / day multiple, intravenous RP2D Dose: 35 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 35 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16028099/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16028099/	Other AEs: Febrile neutropenia, Thrombocytopenia... Other AEs: Febrile neutropenia (grade 3, 1 pt) Thrombocytopenia (grade 3, 1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/16028099/

AEs

PubMed

Title	Date	PubMed
A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.	2010-07	19853960
Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines.	2010-07	19809814
Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases.	2010-06	19415537
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.	2010-05-20	20385980
Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.	2010-04-15	20419121
A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405.	2010-04	19825887
Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats.	2010-04	19697031
The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.	2010-03	20356561
Simple and sensitive HPLC method for determination of amrubicin and amrubicinol in human plasma: application to a clinical pharmacokinetic study.	2010-03	19634123
Treatment options for small cell lung cancer - do we have more choice?	2010-02-16	20104223
Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.	2010-01	19956885
Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).	2010-01	19884859
Emerging drugs for small-cell lung cancer.	2009-12	19694501
Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results.	2009-11-13	19915681
Amrubicin: a synthetic anthracyclin analogue in the treatment of extensive stage small cell lung cancer.	2009-11	19538159
[Two cases of recurrent non-small cell lung cancer successfully treated with S-1 as fifth-line chemotherapy].	2009-10	19838034
Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan.	2009-09-21	19920936
[Pharmacokinetic study of amrubicin in a case of small lung cancer on hemodialysis].	2009-08	19692770
Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.	2009-07	19352172
Thymic small cell carcinoma shows marked response to amrubicin.	2009-06	19461410
A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.	2009-06	19404211
Multiple lung metastases presenting as ground-glass opacities in a pulmonary adenocarcinoma: a case report.	2009-05-29	19829882
[Second-line treatment and targeted therapy of advanced lung cancer].	2009-05	19461168
Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy.	2009-04	19390943
Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor.	2009-03	19212674
Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin.	2009-02-06	19920905
Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens.	2009-02-06	19192640
Amrubicin for the treatment of advanced lung cancer.	2009-02	19239396
Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer.	2009-02	19225927
Effective monotherapy with amrubicin for a refractory extrapulmonary small-cell carcinoma of the liver.	2009	19718248
A case of intimal sarcoma of the pulmonary artery treated with chemoradiotherapy.	2009	19218777
Management of small-cell lung cancer: incremental changes but hope for the future.	2008-11-30	19133604
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.	2008-11-20	18854562
[A case of advanced small cell lung cancer complicated by chronic renal failure treated with amrubicin].	2008-09	18799918
Pulse gradient, large-volume injection, high-throughput ultra-performance liquid chromatographic/tandem mass spectrometry bioanalysis for measurement of plasma amrubicin and its metabolite amrubicinol.	2008-06-06	18452925
Small cell carcinoma of the prostate treated with amrubicin.	2008-04	18463964
Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.	2008-04	18357380
Novel systemic therapies for small cell lung cancer.	2008-03	18377849
[Two cases of severe myelosuppression from amrubicin in previously-treated small cell lung cancer].	2008-03	18347402
[A case of multidrug-resistant squamous cell lung carcinoma responding to S-1 plus CPT-11 combination chemotherapy].	2008-03	18347399
Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.	2008-02-15	18054347
[Our clinical experiences of amrubicin hydrochloride monotherapy in extensive-disease small cell lung cancer].	2008-02	18281764
Current status of clinical trials for small cell lung cancer.	2008-01	18474014
Dose escalation study of amrubicin in combination with fixed-dose irinotecan in patients with extensive small-cell lung cancer.	2008	18536524
[A case of relapsed small-cell lung cancer successfully treated by administration of amrubicin].	2007-12	18186244
[Analysis of adverse events of amrubicin hydrochloride for pretreated lung cancer patients].	2007-11	18030011
Amrubicin for non-small-cell lung cancer and small-cell lung cancer.	2007-10	17628745
Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.	2007-08	17762341
[A case of small cell lung cancer under hemodialysis with chronic renal failure treated with amrubicin while measuring blood concentration of the drug].	2007-04	17491313
Modern management of small-cell lung cancer.	2007	17927281

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose is 45 mg/m2 given intravenously once a day for 3 days.

Route of Administration: Intravenous

In Vitro Use Guide

In a cell viability assay, lung cancer cells DMS 114, NCI-H69, NCI-H82, NCI-H526 were incubated with amrubicin at concentrations from 18 nM to 16 uM for 72 h. IC50 values were 0.803, 1.54, 0.746 and 0.818 uM, respectively.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:13:02 GMT 2025` Edited by `admin` on `Mon Mar 31 18:13:02 GMT 2025`
Record UNII	93N13LB4Z2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMRUBICIN

Official Name

English

AMRUBICIN [MI]

Preferred Name

English

Amrubicin [WHO-DD]

Common Name

English

AMRUBICIN [USAN]

Common Name

English

amrubicin [INN]

Common Name

English

AMRUBICIN [MART.]

Common Name

English

Classification Tree Code System Code

WHO-ATC

L01DB10